Aethlon Medical(US:AEMD) Prnewswire·2025-12-02 13:01Core Insights - Aethlon Medical, Inc. announced a pre-clinical study indicating the potential of the Hemopurifier device in treating Long COVID by targeting extracellular vesicles (EVs) [1][6][4] Company Overview - Aethlon Medical is focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device aimed at treating cancer and life-threatening viral infections [7][8] - The Hemopurifier has received FDA Breakthrough Device designation for treating advanced or metastatic cancer and life-threatening viruses [8] Long COVID Context - Long COVID affects an estimated 44 to 48 million people in the U.S., with a projected economic burden of $2 billion for those experiencing symptoms for a year [2] - Symptoms include fatigue, shortness of breath, and cognitive difficulties, persisting for weeks or months after initial COVID-19 infection [2] Research Findings - The study published on November 20, 2025, demonstrated that the Hemopurifier can remove harmful EVs from the blood, which are implicated in Long COVID [1][5] - Elevated levels of both large and small EVs were found in the plasma of Long COVID patients compared to recovered controls, indicating a potential therapeutic target [5][6] - The GNA affinity resin in the Hemopurifier was shown to deplete specific microRNAs associated with inflammatory pathways, suggesting a mechanism for reducing inflammation in Long COVID [5][6] Future Directions - Aethlon Medical plans to further investigate whether the removal of EVs can decrease SARS-CoV-2 viral particles, which may contribute to Long COVID pathogenesis [6]